Expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases

Chest

Volumn 142, Issue 4, 2012, Pages 1027-1034

  Doyle, Tracy J ^a   Pinto Plata, Victor ^a   Morse, Danielle ^a   Celli, Bartolome R ^a   Rosas, Ivan O ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CC CHEMOKINE LIGAND 18; CLARA CELL PROTEIN 16; CYTOKINE; FIBRINOGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; MUCIN 1; MYELOID PROGENITOR INHIBITORY FACTOR 1; S100A12 PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SURFACTANT PROTEIN D; TNFRSF1A PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; YKL 40 PROTEIN;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL RESEARCH; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE PREDISPOSITION; FIBROSING ALVEOLITIS; HUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SMOKING; TREATMENT RESPONSE;

EID: 84867123261     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1540     Document Type: Article

References (67)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
2. Rosas IO, Yao J, Avila NA, Chow CK, Gahl WA, Gochuico BR. Automated quantification of radiographic changes in populations at risk for pulmonary fibrosis. Chest. 2011;140(6):1590-1597.
3. Yilmaz C, Watharkar SS, Diaz de Leon A, et al. Quantification of regional interstitial lung disease from CT-derived fractional tissue volume: a lung tissue research consortium study. Acad Radiol. 2011;18(8):1014-1023.
4. Washko GR, Lynch DA, Matsuoka S, et al. Identification of early interstitial lung disease in smokers from the COPDGene Study. Acad Radiol. 2010;17(1):48-53.
5. Sin DD, Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(6):543-545.
6. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(1):6-14. (Pubitemid 43955238)
7. Tzoulaki I, Siontis KC, Ioannidis JP. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ. 2011;343:d6829.
8. Dahl M. Biomarkers for chronic obstructive pulmonary dis ease: surfactant protein D and C-reactive protein. Am J Respir Crit Care Med. 2008;177(11):1177-1178. (Pubitemid 351860923)
9. Vestbo J, Edwards LD, Scanlon PD, et al ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184-1192.
10. Celli BR, Locantore N, Yates J, et al ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065-1072.
11. Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax. 2007;62(7):595-601. (Pubitemid 47056886)
12. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(7):588-594.
13. Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS ONE. 2010;5(1):e8959.
14. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer. 2005;5(2):142-149. (Pubitemid 40215862)
15. O'Donoghue M, Morrow DA. The future of biomarkers in the management of patients with acute coronary syndromes. Curr Opin Cardiol. 2008;23(4):309-314. (Pubitemid 351787094)
16. Ransohoff DF. Cancer. Developing molecular biomarkers for cancer. Science. 2003;299(5613):1679-1680.
17. Stockley RA. Biomarkers in COPD: time for a deep breath. Thorax. 2007;62(8):657-660. (Pubitemid 47235002)
18. Stears RL, Martinsky T, Schena M. Trends in microarray analysis. Nat Med. 2003;9(1):140-145. (Pubitemid 36098276)
19. Apple FS, Wu AH, Jaffe AS, et al National Academy of Clinical Biochemistry; IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: analytical issues for biomarkers of heart failure. Circulation. 2007;116(5):e95-e98. (Pubitemid 47450267)
20. Cottin V, Nunes H, Brillet PY, et al; Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586-593.
21. Washko GR, Hunninghake GM, Fernandez IE, et al COPDGene Investigators. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011;364(10):897-906.
22. King TE Jr. Smoking and subclinical interstitial lung disease. N Engl J Med. 2011;364(10):968-970.
23. Cottin V, Le Pavec J, Prévot G, et al; GERM"O"P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35(1):105-111.
24. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574-580. (Pubitemid 38901515)
25. Rosenberg SR, Kalhan R. Biomarkers in chronic obstructive pulmonary disease. Transl Res. 2012;159(4):228-237.
26. Garcia-Rio F, Miravitlles M, Soriano JB, et al EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010;11:63.
27. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27(5):902-907. (Pubitemid 44911101)
28. de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest. 2008;133(6):1336-1343. (Pubitemid 351892988)
29. Dahl M, Vestbo J, Zacho J, Lange P, Tybjærg-Hansen A, Nordestgaard BG. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax. 2011;66(3):197-204.
30. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(3):250-255. (Pubitemid 46203128)
31. Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61(1):23-28. (Pubitemid 43106973)
32. Donaldson GC. C-reactive protein: does it predict mortality? Am J Respir Crit Care Med. 2007;175(3):209-210. (Pubitemid 46203122)
33. Mehrotra N, Freire AX, Bauer DC, et al Health ABC Study. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol. 2010;20(3):223-232.
34. Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med. 2007;7:13.
35. Lomas DA, Silverman EK, Edwards LD, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J. 2009;34(1):95-102.
36. Foreman MG, Kong X, DeMeo DL, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2011;44(3):316-322.
37. Sin DD, Man SF, Marciniuk DD, et al ABC (Advair, Biomarkers in COPD) Investigators. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(11):1207-1214. (Pubitemid 351860929)
38. Sin DD, Miller BE, Duvoix A, et al ECLIPSE Investigators. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(9):1187-1192.
39. Cazzola M, MacNee W, Martinez FJ, et al American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469.
40. Bon JM, Leader JK, Weissfeld JL, et al. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS ONE. 2009;4(8):e6865.
41. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-440.
42. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res. 2012;159(4):218-227.
43. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96(1):68-73. (Pubitemid 19176416)
44. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006;11(2):164-168. (Pubitemid 43356896)
45. Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162(3 pt 1):1109-1114.
46. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009;135(6):1557-1563.
47. Barlo NP, van Moorsel CH, Ruven HJ, Zanen P, van den Bosch JM, Grutters JC. Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):155-161.
48. Greene KE, King TEJ Jr, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19(3):439-446. (Pubitemid 34256957)
49. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc. 2006;3(4):383-388. (Pubitemid 43845417)
50. Huh JW, Kim DS, Oh Y-M, et al. Is metalloproteinase-7 specific for idiopathic pulmonary fibrosis? Chest. 2008;133(5):1101-1106. (Pubitemid 351685512)
51. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5(4):e93.
52. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012;185(11):1147-1153.
53. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185(1):67-76.
54. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(8):717-723.
55. Kono M, Nakamura Y, Suda T, et al. Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta. 2011;412(23-24):2211-2215.
56. Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med. 2010;104(8):1204-1210.
57. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662-671.
58. Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(1):L3-L7.
59. Kashiwabara K. Characteristics and disease activity of early interstitial lung disease in subjects with true parenchymal abnormalities in the posterior subpleural aspect of the lung. Chest. 2006;129(2):402-406. (Pubitemid 43289861)
60. Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med. 2010;104(11):1712-1721.
61. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867-874. (Pubitemid 44564786)
62. Shakoori TA, Sin DD, Ghafoor F, Bashir S, Bokhari SN. Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease. Dis Markers. 2009;27(6):287-294.
63. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155(1):242-248. (Pubitemid 27053171)
64. Flaherty KR, Hunninghake GG. Smoking: an injury with many lung manifestations. Am J Respir Crit Care Med. 2005;172(9):1070-1071. (Pubitemid 43066640)
65. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31(6):1334-1356.
66. LGRC: Lung Genomics Research Consortium. Lung Genomics Research Consortium website. http://www.lung-genomics.org/. Accessed July 26, 2012.
67. Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest. 2012;141(2):396-405.